Mahshid Mehdizadeh - Shahid Beheshti university of medical sciences

A variety of hematological disorders of the bone marrow, such as acute leukemia, chronicmyelocytic leukemia and severe aplastic anemia, were invariably known as fatal disorders. In the past two decades, physicians have been able to change this reality into a more hopeful outcome byreplacing the diseased bone marrow with stem cells from either a family or an unrelated donor with identical human leukocyte antigens (HLA).Based on the rapid progression in the field of stem cell transplantation donor banks now are considered a necessity.Considering stem cell transplantation we can treat some malignant disorders with Intending to cure.Timing of hematopoietic stem cell transplantation is the most important point to achieve cure in malignant disorders. Distinct indications are shown for HSCT in Acute myeloblastic and lymphoblastic leukemia, aplastic anemia, multiple myeloma and relapsed Hodgkin and non Hodgkin lymphomas which benefit the most. Preparing the patients for on time HSCT is key point of success. Achievement of complete remission before HSCT and finding the best donor in family members or unrelated ones are corner stones of transplantation .There are someethical concerns for donors and families, concerns that need to be discussed and understood by patients, donors and health care professionals.

stem cell,hematopoietic,transplantation,malignancy